Determining whether Humacyte is undervalued depends heavily on an investor's outlook regarding the commercial adoption of its flagship bioengineered vessels. Proponents argue that current micro-cap share prices undervalue the long-term multi-billion-dollar total addressable market for regenerative tissue products in military and civilian trauma. Conversely, skeptics counter that lower valuations reflect persistent operating losses, slow initial commercial revenue ramps, and necessary future capital dilutive raises.